M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
73 deals · US$14bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Sep 2026 | ADARx Pharmaceuticals | – | – | IPO | Announced | 446.3 | Biotech+1 | Cooley (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)TD Securities (lead manager)UBS (lead manager)LifeSci Capital (lead manager)Latham & Watkins (lead manager) |
| Sep 2026 | ADARx Pharmaceuticals | – | – | Placement | Announced | 89.0 | Biotech+1 | J.P. Morgan (lead manager)Morgan Stanley (lead manager)TD Securities (lead manager)UBS (lead manager)LifeSci Capital (lead manager) |
| Sep 2026 | Marea Therapeutics | – | – | Placement | Announced | 225.0 | Biotech | Cooley (lead manager) |
| Sep 2026 | North Immunology | – | – | Placement | Announced | 180.0 | Biotech | Cooley (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)BofA Securities (lead manager)UBS (lead manager) |
| Sep 2026 | Electra Therapeutics | – | – | IPO | Announced | 350.0 | Biotech+1 | Cooley (issuer)Jefferies (lead manager)TD Securities (lead manager)Evercore (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Sep 2026 | Pyxis Oncology | – | – | Follow-on offering | Announced | 110.0 | Biotech+1 | Latham & Watkins (lead manager) |
| Aug 2026 | Amylyx Pharmaceuticals | – | – | Follow-on offering | Announced | 575.2 | Biotech+1 | Goodwin (issuer)Leerink Partners (lead manager)Morgan Stanley (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager) |
| Aug 2026 | AbCellera Biologics | – | – | Follow-on offering | Completed | 200.0 | Biotech+1 | Goodwin (issuer) |
| Aug 2026 | Ambros Therapeutics | – | – | Placement | Announced | 150.0 | Biotech+1 | Cooley (issuer) |
| Aug 2026 | Werewolf Therapeutics | – | – | Placement | Announced | 150.0 | Biotech+2 | Leerink Partners (lead manager)Piper Sandler (lead manager)Cantor Fitzgerald (lead manager)Wells Fargo Securities (lead manager)LifeSci Capital (lead manager)Latham & Watkins (lead manager) |
| Aug 2026 | Redx Pharma | – | – | Placement | Announced | 125.0 | Biotech+1 | Cooley (issuer) |
| Aug 2026 | Silence Therapeutics | – | – | Placement | Completed | 201.0 | Biotech+1 | Goodwin (lead manager)Jefferies (lead manager)Morgan Stanley (lead manager)Cantor Fitzgerald (lead manager)William Blair (lead manager) |
| Aug 2026 | Slate Medicines | – | – | Placement | Announced | 245.0 | Biotech+1 | Cooley (issuer) |
| Aug 2026 | Skye Bioscience | – | – | Placement | Announced | 68.0 | Biotech+1 | Leerink Partners (lead manager)MTS Health Partners (lead manager)Mintz (lead manager) |
| Aug 2026 | Braveheart Bio | – | – | IPO | Listed | 382.5 | Biotech+2 | Goodwin (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Cantor Fitzgerald (lead manager)Covington & Burling (lead manager) |
| Aug 2026 | Ensysce Biosciences | – | – | Placement | Announced | 43.0 | Biotech+1 | Cantor Fitzgerald (lead manager)UBS (lead manager)Mintz (lead manager) |
| Aug 2026 | Attovia Therapeutics | – | – | IPO | Listed | 289.0 | Biotech+1 | Fenwick & West (issuer)Morgan Stanley (lead manager)Leerink Partners (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)LifeSci Capital (lead manager)Cooley (lead manager) |
| Aug 2026 | BlossomHill Therapeutics | – | – | IPO | Listed | 150.0 | Biotech+2 | Cooley (issuer)J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)H.C. Wainwright & Co. (lead manager)Latham & Watkins (lead manager) |
| Aug 2026 | Latigo Biotherapeutics | – | – | IPO | Listed | 345.6 | Biotech+2 | Cooley (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)Latham & Watkins (lead manager) |
| Jul 2026 | Apnimed | – | – | IPO | Listed | 192.0 | Biotech+1 | Goodwin (issuer)BofA Securities (lead manager)Evercore (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Cleary Gottlieb Steen & Hamilton (lead manager) |
| Jul 2026 | Caldera Therapeutics | – | – | Placement | Announced | 278.0 | Biotech+1 | Jefferies (lead manager)TD Securities (lead manager)Guggenheim Securities (lead manager)UBS (lead manager)LifeSci Capital (lead manager)Cooley (lead manager) |
| Jul 2026 | Inovio Pharmaceuticals | – | – | Follow-on offering | Completed | – | Biotech+1 | Piper Sandler (issuer) |
| Jul 2026 | Processa Pharmaceuticals | – | – | Placement | Announced | 200.0 | Biotech+1 | Leerink Partners (lead manager)Evercore (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)Mintz (lead manager) |
| Jul 2026 | Research Alliance Corporation III | – | – | Placement | Announced | 100.0 | Biotech+2 | Leerink Partners (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)LifeSci Capital (lead manager)Kirkland & Ellis (lead manager) |
| Jul 2026 | Codexis | – | – | Follow-on offering | Completed | – | Biotech+1 | Piper Sandler (lead manager) |
| Jul 2026 | Scancell Holdings | – | – | Placement | Announced | 54.1 | Biotech+1 | Cooley (issuer)Leerink Partners (lead manager)TD Securities (lead manager)H.C. Wainwright & Co. (lead manager)Mintz (lead manager)Panmure Liberum (lead manager) |
| Jul 2026 | Scribe Therapeutics | – | – | IPO | Listed | 128.7 | Biotech+1 | Fenwick & West (issuer)Leerink Partners (lead manager)Goldman Sachs (lead manager)Guggenheim Securities (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager) |
| Jul 2026 | Jasper Therapeutics | – | – | Placement | Announced | 132.0 | Biotech+1 | Piper Sandler (lead manager)LifeSci Capital (lead manager) |
| Jul 2026 | Avere Therapeutics | – | – | Placement | Announced | 320.0 | Biotech+1 | Sullivan & CromwellGibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)Wedbush Securities (lead manager) |
| Jul 2026 | BridgeBio Pharma | – | – | Placement | Announced | 1,000.0 | Biotech+1 | EvercoreSullivan & CromwellMintzGibson DunnLatham & Watkins (issuer) |
| Jun 2026 | Alebund Pharmaceuticals (Jiangsu) | – | – | IPO | Listed | – | Biotech+1 | Jefferies (lead manager)BofA Securities (lead manager)Huatai Securities (lead manager)Davis Polk (issuer)Kirkland & Ellis (lead manager)CITIC CLSA (lead manager)BOCI (lead manager) |
| Jun 2026 | JATT II Acquisition Corp | – | – | Placement | Announced | 225.0 | Biotech+1 | Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Davis Polk (lead manager) |
| Jun 2026 | Remix Therapeutics | – | – | Placement | Pending | 100.0 | Biotech+2 | Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Cooley (lead manager) |
| Jun 2026 | HJ Science Co. | – | – | IPO | Listed | – | Biotech+1 | Sidley Austin (issuer)CITIC CLSA (lead manager) |
| Jun 2026 | Kardigan | – | – | IPO | Listed | 400.0 | Biotech+2 | Goodwin (issuer)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Latham & Watkins (lead manager) |
| Jun 2026 | Parabilis Medicines | – | – | Placement | Completed | 75.0 | Biotech+1 | Goodwin (issuer) |
| Jun 2026 | Adial Pharmaceuticals | – | – | Placement | Pending | 32.0 | Biotech+1 | TD Securities (issuer)Lucid Capital Markets (lead manager) |
| Jun 2026 | Parabilis Medicines | – | – | IPO | Listed | 670.0 | Biotech+2 | Goodwin (issuer)Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)Covington & Burling (lead manager) |
| Jun 2026 | Avenzo Therapeutics | – | – | Placement | Pending | 215.0 | Biotech+2 | Leerink Partners (lead manager)Goldman Sachs (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Mintz (lead manager) |
| May 2026 | Mentari Therapeutics | – | – | Placement | Announced | 290.0 | Biotech+1 | Gibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Guggenheim Securities (lead manager)Wedbush Securities (lead manager) |
| May 2026 | Optimi Health Corp. | – | – | Follow-on offering | Announced | 15.0 | Biotech+2 | Norton Rose Fulbright (issuer)Joseph Gunnar & Co. (lead manager)Cozen O'Connor (lead manager) |
| May 2026 | Quince Therapeutics | – | – | Placement | Announced | 115.0 | Biotech+2 | EvercoreCantor FitzgeraldLifeSci Capital (lead manager)Gibson Dunn (lead manager) |
| May 2026 | IMPACT Therapeutics | – | – | IPO | Listed | – | Biotech+2 | Cooley (issuer)Goldman Sachs (lead manager)CICC (lead manager)Kirkland & Ellis (lead manager) |
| May 2026 | METiS TechBio | – | – | IPO | Announced | – | Biotech+2 | Davis Polk (issuer) |
| May 2026 | Odyssey Therapeutics | – | – | IPO | Announced | 279.0 | Biotech+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) |
| May 2026 | Odyssey Therapeutics | – | – | Placement | Pending | 25.0 | Biotech+1 | J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) |
| Apr 2026 | Hemab Therapeutics Holdings | – | – | IPO | Announced | 301.5 | Biotech+1 | WilmerHale (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager) |
| Apr 2026 | Seaport Therapeutics | – | – | IPO | Announced | 254.9 | Biotech+1 | Goodwin (issuer)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
| Apr 2026 | Avalyn Pharma | – | – | IPO | Listed | 300.0 | Biotech+2 | Goodwin (issuer)Morgan Stanley (lead manager)Jefferies (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Davis Polk (lead manager) |
| Apr 2026 | Opus Genetics | – | – | Placement | Announced | 5.0 | Biotech+1 | Sidley Austin (issuer) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.